07February

Novo Nordisk invests DKK 800 million in upgrading and expanding production facil ... Read more

05February

Novo Nordisk files annual report with the SEC ... Read more

05February

Novo Nordisk's operating profit increased by 11% in Danish kroner and by 6% at c ... Read more

31January

Rybelsus® (oral semaglutide) recommended for approval for the treatment of adult ... Read more

14February

Novo Nordisk A/S – Share repurchase programme ... Read more

14February

Trading in Novo Nordisk shares by board members, executives and associated perso ... Read more

11February

Trading in Novo Nordisk shares by board members, executives and associated perso ... Read more

10February

Trading in Novo Nordisk shares by board members, executives and associated perso ... Read more

26March

Annual General Meeting, Copenhagen

01April

Silent period,

06May

Financial statements for the first three months of 2020,

01July

Silent period,

 

 

 

Investors

Share information
 

Capital markets day


Capital Markets Day 2019 
- Webcast and presentations

SHARE Magazine


Get the latest SHARE Magazine
- news for you as an investor

Corporate reporting

Rybelsus® US approval

 



Access conference call
- Webcast and presentation

Private shareholders


Shareholder tools and systems for private investors

 

Investor materials

Contact Investor Relations

Sign-up: Company announcements


Sign up and receive our company announcements

 

Financial results and events overview